Oriella Gnarra

Dr. Oriella Gnarra

ETH Zurich, Zürich, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2021 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SAStefania Ancona
Stefania Ancona
FFFrancesca D. Faraci
Francesca D. Faraci
EKElina Khatab
Elina Khatab
LFLuigi Fiorillo
Luigi Fiorillo
OGOriella Gnarra
Oriella Gnarra
Panagiotis BargiotasPanagiotis Bargiotas
Panagiotis Bargiotas

13 December 2023 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
LSLuigi Ferini Strambi
Luigi Ferini Strambi
CLClaudio Liguori
Claudio Liguori
BLBrendan P Lucey
Brendan P Lucey
BMBryce A Mander
Bryce A Mander
ASAdam P Spira
Adam P Spira
CBClaudio Bassetti
Claudio Bassetti

15 February 2023 in SLEEP
Verified
Journal Article
Closed access
PDF file
OGOriella Gnarra
Oriella Gnarra
MWMarie-Angela Wulf
Marie-Angela Wulf
CSCarolin Schäfer
Carolin Schäfer
TNTobias Nef
Tobias Nef
Claudio L.A. BassettiClaudio L.A. Bassetti
Claudio L.A. Bassetti
Study objectives: Isolated rapid eye movement sleep behavior disorder (iRBD) is a parasomnia characterized by dream enactment. It represents a prodromal state of α-synucleinopathies, like Parkinson’s disease. In recent years, biomarkers of increased risk of phenoconversion from iRBD to overt α-synucleinopathies have been identified. Currently, diagnosis and monitoring rely on self-reported reports and polysomnography (PSG) performed in the sleep lab, which is limited in availability and cost-intensive. Wearable technologies and computerized algorithms may provide comfortable and cost-efficient means to not only improve the identification of patients with iRBD but also to monitor risk factors of phenoconversion. In this work, we review studies using these technologies to identify iRBD or monitor phenoconversion biomarkers. Methods: A review of articles published until May 31, 2022 using the Medline database was performed. We included only papers in which participants with RBD were part of the study population. The selected papers were divided into four sessions: actigraphy, gait analysis systems, computerized algorithms, and novel technologies. Results: In total, 25 articles were included in the review. Actigraphy, wearable accelerometers, pressure mats, smartphones, tablets, and algorithms based on PSG signals were used to identify RBD and monitor the phenoconversion. Rest–activity patterns, core body temperature, gait, and sleep parameters were able to identify the different stages of the disease. Conclusions: These tools may complement current diagnostic systems in the future, providing objective ambulatory data obtained comfortably and inexpensively. Consequently, screening for iRBD and follow-up will be more accessible for the concerned patient cohort.

29 March 2024 in SLEEP
Verified
Journal Article
Closed access
PDF file
OGOriella Gnarra
Oriella Gnarra
JMJulia van der Meer
Julia van der Meer
JWJan Warncke
Jan Warncke
LFLivia G Fregolente
Livia G Fregolente
EWElena Sophie Wenz
Elena Sophie Wenz
MSMarkus Schmidt
Markus Schmidt
The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (SPHYNCS) is a multicenter research initiative to identify new biomarkers in central disorders of hypersomnolence (CDH). Whereas narcolepsy type 1 (NT1) is well characterized, other CDH disorders lack precise biomarkers. In SPHYNCS, we utilized Fitbit smartwatches to monitor physical activity, heart rate, and sleep parameters over 1 year. We examined the feasibility of long-term ambulatory monitoring using the wearable device. We then explored digital biomarkers differentiating patients with NT1 from healthy controls (HC). A total of 115 participants received a Fitbit smartwatch. Using a adherence metric to evaluate the usability of the wearable device, we found an overall adherence rate of 80% over 1 year. We calculated daily physical activity, heart rate, and sleep parameters from 2 weeks of greatest adherence to compare NT1 (n = 20) and HC (n = 9) participants. Compared to controls, NT1 patients demonstrated findings consistent with increased sleep fragmentation, including significantly greater wake-after-sleep onset (p = .007) and awakening index (p = .025), as well as standard deviation of time in bed (p = .044). Moreover, NT1 patients exhibited a significantly shorter REM latency (p = .019), and sleep latency (p = .001), as well as a lower peak heart rate (p = .008), heart rate standard deviation (p = .039) and high-intensity activity (p = .009) compared to HC. This ongoing study demonstrates the feasibility of long-term monitoring with wearable technology in patients with CDH and potentially identifies a digital biomarker profile for NT1. While further validation is needed in larger datasets, these data suggest that long-term wearable technology may play a future role in diagnosing and managing narcolepsy.

10 November 2023 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
OGOriella Gnarra
Oriella Gnarra
CCCarmen Calvello
Carmen Calvello
TSTommaso Schirinzi
Tommaso Schirinzi
FBFrancesca Beozzo
Francesca Beozzo
CMClaudia De Masi
Claudia De Masi
CLClaudio Liguori
Claudio Liguori
Patients with Parkinson’s disease (PD) tend to sleep more frequently in the supine position and less often change head and body position during sleep. Besides sleep quality and continuity, head and body positions are crucial for glymphatic system (GS) activity. This pilot study evaluated sleep architecture and head position during each sleep stage in idiopathic PD patients without cognitive impairment, correlating sleep data to patients’ motor and non-motor symptoms (NMS). All patients underwent the multi-night recordings, which were acquired using the Sleep Profiler headband. Sleep parameters, sleep time in each head position, and percentage of slow wave activity (SWA) in sleep, stage 3 of non-REM sleep (N3), and REM sleep in the supine position were extracted. Lastly, correlations with motor impairment and NMS were performed. Twenty PD patients (65.7 ± 8.6 y.o, ten women) were included. Sleep architecture did not change across the different nights of recording and showed the prevalence of sleep performed in the supine position. In addition, SWA and N3 were more frequently in the supine head position, and N3 in the supine decubitus correlated with REM sleep performed in the same position; this latter correlated with the disease duration (correlation coefficient = 0.48, p-value = 0.03) and motor impairment (correlation coefficient = 0.53, p-value = 0.02). These preliminary results demonstrated the importance of monitoring sleep in PD patients, supporting the need for preventive strategies in clinical practice for maintaining the lateral head position during the crucial sleep stages (SWA, N3, REM), essential for permitting the GS function and activity and ensuring brain health.

Verified
Journal Article
Open access
PDF file
KSKaspar Schindler
Kaspar Schindler
TNTobias Nef
Tobias Nef
MBMaxime Baud
Maxime Baud
ATAthina Tzovara
Athina Tzovara
GYGürkan Yilmaz
Gürkan Yilmaz
Claudio L.A. BassettiClaudio L.A. Bassetti
Claudio L.A. Bassetti
Neurology is focused on a model where patients receive their care through repeated visits to clinics and doctor’s offices. Diagnostic tests often require expensive and specialized equipment that are only available in clinics. However, this current model has significant drawbacks. First, diagnostic tests, such as daytime EEG and sleep studies, occur under artificial conditions in the clinic, which may mask or wrongly emphasize clinically important features. Second, early detection and high-quality management of chronic neurological disorders require repeat measurements to accurately capture the dynamics of the disease process, which is impractical to execute in the clinic for economical and logistical reasons. Third, clinic visits remain inaccessible to many patients due to geographical and economical circumstances. Fourth, global disruptions to daily life, such as the one caused by COVID-19, can seriously harm patients if access to in-person clinical visits for diagnostic and treatment purposes is throttled. Thus, translating diagnostic and treatment procedures to patients’ homes will convey multiple substantial benefits and has the potential to substantially improve clinical outcomes while reducing cost. NeuroTec was founded to accelerate the re-imagining of neurology and to promote the convergence of technological, scientific, medical and societal processes. The goal is to identify and validate new digital biomarkers that can close the last mile in neurology by enabling the translation of personalized diagnostics and therapeutic interventions from the clinic to the patient’s home.